XW133H9
Transfusion Peripheral Vein to New Technology Group 9 with Lovotibeglogene Autotemcel, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 1 Transfusion |
| Body Part | 3 Peripheral Vein |
| Approach | 3 Percutaneous |
| Device | H Lovotibeglogene Autotemcel |
| Qualifier | 9 New Technology Group 9 |
Operation Definition
Putting in blood or blood products
Procedure Overview
This family applies specifically to putting blood or blood products into a patient using a New Technology-designated product, distinguishing it from routine transfusions of standard blood components. It exists because certain newer blood-derived products, engineered or processed differently from conventional units, are tracked separately to monitor their use and outcomes.
A patient receiving this kind of transfusion is usually being treated for a condition where standard blood products have proven insufficient, such as certain bleeding disorders or infections, and the care team has opted for a product with novel approval status.
Anatomy & Axis Detail
Peripheral Vein
Transfusion into a peripheral vein under this New Technology code describes infusing a novel blood product or biologic engineered substance through a vein in the arm, hand, leg, or foot rather than a central line. Peripheral veins are chosen for their accessibility and lower procedural risk, making them the default route when the infused product does not require central administration and the patient's peripheral venous access is adequate. Because these transfusions involve substances still classified under New Technology, documentation should identify the specific product, such as an engineered blood component or novel plasma-derived therapy, separately from the vein used for access. Clinicians should also note the specific peripheral vein accessed, since peripheral versus central administration can affect infusion rate, monitoring needs, and how the episode is coded relative to standard transfusion procedures.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Lovotibeglogene Autotemcel
Lovotibeglogene autotemcel (marketed as Lyfgenia) denotes administration of an autologous hematopoietic stem cell gene therapy that adds a modified beta-globin gene to treat sickle cell disease and reduce vaso-occlusive events. It differs from exagamglogene autotemcel, which achieves a similar clinical goal through CRISPR gene editing rather than viral vector gene addition, and from betibeglogene autotemcel, which targets beta-thalassemia.
Qualifier: New Technology Group 9
Group 9 is the seventh-position qualifier used in the New Technology section to mark a device, substance, or technique as belonging to the 2022 annual cohort of new technology add-on codes. It has no clinical meaning of its own beyond that vintage tag, so coders rely on the specific table and body system to know what procedure it applies to. It is distinguished from Group 8 and Group 10 purely by the fiscal year the technology was approved for separate identification.
Coding & Documentation
The documentation needs to specify the exact blood product given, since this family is tied to specific New Technology-approved products rather than blood transfusion in general. Coders should confirm the product name against current approval lists before assigning a code here rather than to a standard transfusion code.
The most common mistake is coding a novel-sounding product under routine transfusion codes, or conversely, assuming any unfamiliar blood product automatically belongs in this family without checking that it actually holds New Technology status.
Commonly Confused With
This is easily confused with standard blood transfusion codes found in the Administration section. The difference comes down entirely to whether the specific product administered has been given New Technology recognition, not the clinical reason for the transfusion or the route used.